{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:31Z","timestamp":1791903511133,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-11-153-01-LIB"],"award-info":[{"award-number":["RSG-11-153-01-LIB"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001453","name":"American Brain Tumor Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006398","name":"Roswell Park Alliance Foundation, Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mr. Phillip H. Hubbell"},{"name":"Linda Scime Endowment"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30 CA16056-29"],"award-info":[{"award-number":["5P30 CA16056-29"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00262-016-1890-x","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T04:25:51Z","timestamp":1472531151000},"page":"1339-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma"],"prefix":"10.1007","volume":"65","author":[{"given":"Robert A.","family":"Fenstermaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3373-9421","authenticated-orcid":false,"given":"Michael J.","family":"Ciesielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl L.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin P.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo R.","family":"Mechtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Belal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"key":"1890_CR1","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/25141","volume":"396","author":"F Li","year":"1998","unstructured":"Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580\u2013584. doi:\n                    10.1038\/25141","journal-title":"Nature"},{"key":"1890_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917\u2013921","journal-title":"Nat Med"},{"key":"1890_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0","volume":"92","author":"K Satoh","year":"2001","unstructured":"Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271\u2013278","journal-title":"Cancer"},{"key":"1890_CR4","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/cncr.11122","volume":"97","author":"Y Kajiwara","year":"2003","unstructured":"Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K, Arita K, Kurisu K (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97:1077\u20131083. doi:\n                    10.1002\/cncr.11122","journal-title":"Cancer"},{"key":"1890_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98\u2013110. doi:\n                    10.1016\/j.ccr.2009.12.020","journal-title":"Cancer Cell"},{"key":"1890_CR6","first-page":"43","volume":"152","author":"C Adida","year":"1998","unstructured":"Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43\u201349","journal-title":"Am J Pathol"},{"key":"1890_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11060-004-2353-3","volume":"72","author":"M Uematsu","year":"2005","unstructured":"Uematsu M, Ohsawa I, Aokage T, Nishimaki K, Matsumoto K, Takahashi H, Asoh S, Teramoto A, Ohta S (2005) Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 72:231\u2013238. doi:\n                    10.1007\/s11060-004-2353-3","journal-title":"J Neurooncol"},{"key":"1890_CR8","doi-asserted-by":"publisher","first-page":"e1008347","DOI":"10.1080\/2162402X.2015.1008347","volume":"4","author":"L Muller","year":"2015","unstructured":"Muller L, Muller-Haegele S, Mitsuhashi M, Gooding W, Okada H, Whiteside TL (2015) Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology 4:e1008347. doi:\n                    10.1080\/2162402X.2015.1008347","journal-title":"Oncoimmunology"},{"key":"1890_CR9","first-page":"5964","volume":"61","author":"MH Andersen","year":"2001","unstructured":"Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964\u20135968","journal-title":"Cancer Res"},{"key":"1890_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0065-230X(03)88303-3","volume":"88","author":"DC Altieri","year":"2003","unstructured":"Altieri DC (2003) Survivin and apoptosis control. Adv Cancer Res 88:31\u201352","journal-title":"Adv Cancer Res"},{"key":"1890_CR11","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s00262-010-0845-x","volume":"59","author":"MJ Ciesielski","year":"2010","unstructured":"Ciesielski MJ, Ahluwalia MS, Munich SA, Orton M, Barone T, Chanan-Khan A, Fenstermaker RA (2010) Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother 59:1211\u20131221. doi:\n                    10.1007\/s00262-010-0845-x","journal-title":"Cancer Immunol Immunother"},{"key":"1890_CR12","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00262-008-0510-9","volume":"57","author":"MJ Ciesielski","year":"2008","unstructured":"Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA (2008) Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 57:1827\u20131835. doi:\n                    10.1007\/s00262-008-0510-9","journal-title":"Cancer Immunol Immunother"},{"key":"1890_CR13","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1084\/jem.188.12.2357","volume":"188","author":"K Hung","year":"1998","unstructured":"Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357\u20132368","journal-title":"J Exp Med"},{"key":"1890_CR14","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1073\/pnas.96.10.5340","volume":"96","author":"DM Pardoll","year":"1999","unstructured":"Pardoll DM (1999) Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci USA 96:5340\u20135342","journal-title":"Proc Natl Acad Sci USA"},{"key":"1890_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1586\/14760584.2014.881255","volume":"13","author":"RA Fenstermaker","year":"2014","unstructured":"Fenstermaker RA, Ciesielski MJ (2014) Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma. Expert Rev Vaccines 13:377\u2013385. doi:\n                    10.1586\/14760584.2014.881255","journal-title":"Expert Rev Vaccines"},{"key":"1890_CR16","first-page":"1815","volume":"60","author":"J Rohayem","year":"2000","unstructured":"Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K, Rieber EP (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60:1815\u20131817","journal-title":"Cancer Res"},{"key":"1890_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.4161\/cbt.5.5.2652","volume":"5","author":"SR Hadrup","year":"2006","unstructured":"Hadrup SR, Gehl J, Sorensen RB, Geertsen PF, Straten PT, Andersen MH (2006) Persistence of survivin specific T cells for seven years in a melanoma patient during complete remission. Cancer Biol Ther 5:480\u2013482","journal-title":"Cancer Biol Ther"},{"key":"1890_CR18","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/clinchem\/47.9.1729","volume":"47","author":"A Yagihashi","year":"2001","unstructured":"Yagihashi A, Asanuma K, Nakamura M, Araya J, Mano Y, Torigoe T, Kobayashi D, Watanabe N (2001) Detection of anti-survivin antibody in gastrointestinal cancer patients. Clin Chem 47:1729\u20131731","journal-title":"Clin Chem"},{"key":"1890_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4161\/cbt.3.2.611","volume":"3","author":"S Reker","year":"2004","unstructured":"Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, Andersen MH (2004) Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther 3:173\u2013179","journal-title":"Cancer Biol Ther"},{"key":"1890_CR20","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00262-006-0138-6","volume":"55","author":"MJ Ciesielski","year":"2006","unstructured":"Ciesielski MJ, Apfel L, Barone TA, Castro CA, Weiss TC, Fenstermaker RA (2006) Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 55:1491\u20131503. doi:\n                    10.1007\/s00262-006-0138-6","journal-title":"Cancer Immunol Immunother"},{"key":"1890_CR21","doi-asserted-by":"publisher","first-page":"230","DOI":"10.4172\/2157-7560.1000230","volume":"5","author":"MJ Ciesielski","year":"2014","unstructured":"Ciesielski MJ, Qiu J, Fenstermaker RA (2014) Survivin as a Cancer Vaccine Target. J Vaccines Vaccin. 5:230. doi:\n                    10.4172\/2157-7560.1000230","journal-title":"J Vaccines Vaccin."},{"key":"1890_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1615\/CritRevImmunol.v20.i6.10","volume":"20","author":"WW Overwijk","year":"2000","unstructured":"Overwijk WW, Restifo NP (2000) Autoimmunity and the immunotherapy of cancer: targeting the \u201cself\u201d to destroy the \u201cother\u201d. Crit Rev Immunol 20:433\u2013450","journal-title":"Crit Rev Immunol"},{"key":"1890_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/sj.bjc.6602317","volume":"92","author":"JR Fangusaro","year":"2005","unstructured":"Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR, Hayes J, Altura RA (2005) Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 92:359\u2013365. doi:\n                    10.1038\/sj.bjc.6602317","journal-title":"Br J Cancer"},{"key":"1890_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/sj.bjc.6604253","volume":"98","author":"J Nakano","year":"2008","unstructured":"Nakano J, Huang C, Liu D, Masuya D, Yokomise H, Ueno M, Haba R, Sumitomo S (2008) The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer 98:1109\u20131117. doi:\n                    10.1038\/sj.bjc.6604253","journal-title":"Br J Cancer"},{"key":"1890_CR25","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1158\/1078-0432.CCR-14-0820","volume":"20","author":"MG Castro","year":"2014","unstructured":"Castro MG, Baker GJ, Lowenstein PR (2014) Blocking immunosuppressive checkpoints for glioma therapy: the more the merrier! Clin Cancer Res 20:5147\u20135149. doi:\n                    10.1158\/1078-0432.CCR-14-0820","journal-title":"Clin Cancer Res"},{"key":"1890_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ijc.26365","volume":"131","author":"M Widenmeyer","year":"2012","unstructured":"Widenmeyer M, Griesemann H, Stevanovic S et al (2012) Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 131:140\u2013149. doi:\n                    10.1002\/ijc.26365","journal-title":"Int J Cancer"},{"key":"1890_CR27","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1016\/j.vaccine.2008.05.036","volume":"26","author":"EK Kim","year":"2008","unstructured":"Kim EK, Cho HI, Yoon SH, Park MJ, Sohn HJ, Kim HJ, Oh ST, Kim TG (2008) Efficient generation of survivin-specific cytotoxic T lymphocytes from healthy persons in vitro: quantitative and qualitative effects of CD4+ T cells. Vaccine 26:3987\u20133997. doi:\n                    10.1016\/j.vaccine.2008.05.036","journal-title":"Vaccine"},{"key":"1890_CR28","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1158\/0008-5472.CAN-07-1141","volume":"67","author":"M Moeller","year":"2007","unstructured":"Moeller M, Kershaw MH, Cameron R, Westwood JA, Trapani JA, Smyth MJ, Darcy PK (2007) Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells. Cancer Res 67:11428\u201311437. doi:\n                    10.1158\/0008-5472.CAN-07-1141","journal-title":"Cancer Res"},{"key":"1890_CR29","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2326-6066.CIR-14-0036","volume":"3","author":"L Shen","year":"2015","unstructured":"Shen L, Sundstedt A, Ciesielski M et al (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136\u2013148. doi:\n                    10.1158\/2326-6066.CIR-14-0036","journal-title":"Cancer Immunol Res"},{"key":"1890_CR30","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","volume":"17","author":"ET Wong","year":"1999","unstructured":"Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572\u20132578","journal-title":"J Clin Oncol"},{"key":"1890_CR31","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","volume":"48","author":"R Stupp","year":"2012","unstructured":"Stupp R, Wong ET, Kanner AA et al (2012) NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192\u20132202. doi:\n                    10.1016\/j.ejca.2012.04.011","journal-title":"Eur J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1890-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T07:25:50Z","timestamp":1589613950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1890-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1890-x","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]},"assertion":[{"value":"18 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"R.A. Fenstermaker and M.J. Ciesielski are co-inventors on patents regarding SVN53-67\/M57-KLH and are co-founders of MimiVax, LLC, which has licensed such patents from Roswell Park Cancer Institute. No additional potential conflicts of interest were disclosed by the other authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}